Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab,...

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being investigated globally in a multi-center Phase Ib...

Moatable Declares Special Cash Dividend of US$0.6057 per ADS and Ex-Dividend Date

Moatable Declares Special Cash Dividend of US$0.6057 per ADS and Ex-Dividend Date

PHOENIX, March 5, 2025 /PRNewswire/ -- Moatable, Inc. (OTC Pink: MTBLY) ("Moatable" or the "Company"), an operator of several US-based SaaS businesses, today announced that its Board of Directors has declared a special cash dividend (the "Special...

QNAP Empowers Professionals with TS-h1277AFX All-flash NAS, Engineered for Intensive Creative and Virtual Workloads

QNAP Empowers Professionals with TS-h1277AFX All-flash NAS, Engineered for Intensive Creative and Virtual Workloads

TAIPEI, March 5, 2025 /PRNewswire/ -- QNAP® Systems, Inc. , a leading innovator in computing, networking, and storage solutions, has unveiled the TS-h1277AFX, a 12-bay tower all-flash NAS designed to meet the rigorous demands of multimedia...

Baidu Announces Proposed Offering of CNY-denominated Senior Notes

Baidu Announces Proposed Offering of CNY-denominated Senior Notes

BEIJING, March 5, 2025 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it proposes to offer...

MWC Barcelona 2025 Fibocom Debuts Compact, Low-Power Cat.M Module MQ780-GL Powered by Qualcomm Modem-RF

MWC Barcelona 2025 Fibocom Debuts Compact, Low-Power Cat.M Module MQ780-GL Powered by Qualcomm Modem-RF

BARCELONA, Spain, March 5, 2025 /PRNewswire/ -- Fibocom (Stock code:300638), a global leading provider of AIoT solutions and wireless communication modules, has unveiled its new MQ780-GL Cat.M module embedded with the Qualcomm® E51 4G Modem-RF....

MWC Barcelona 2025: Fibocom Launches Qualcomm X85/X82 5G Modem-RF-Powered 5G Modules, Enhancing FWA AI Capabilities

MWC Barcelona 2025: Fibocom Launches Qualcomm X85/X82 5G Modem-RF-Powered 5G Modules, Enhancing FWA AI Capabilities

BARCELONA, Spain, March 4, 2025 /PRNewswire/ -- Fibocom (Stock code:300638), a global leading provider of AIoT solutions and wireless communication modules, announced the launch of its new 5G modules and solutions based on Qualcomm Technologies,...

CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong

CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong

DALIAN, China, March 3, 2025 /PRNewswire/ -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy", or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced its participation in the...

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced...

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

  • 1
  • ...
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • ...
  • 46
  • menu
    menu